{"id":85637,"date":"2026-05-12T12:55:03","date_gmt":"2026-05-12T07:25:03","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=85637"},"modified":"2026-05-12T12:55:05","modified_gmt":"2026-05-12T07:25:05","slug":"goldline-pharmaceutical-ipo-gmp-day-1-may-12-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/goldline-pharmaceutical-ipo-gmp-day-1-may-12-2026\/","title":{"rendered":"Goldline Pharmaceutical IPO Opens Today 12 May 2026: GMP at Rs 16-17 Signals 37-40% Listing Gain, Price Band Rs 41-43"},"content":{"rendered":"

The Goldline Pharmaceutical IPO<\/strong> opens for subscription today, 12 May 2026, on the BSE SME platform with a price band of Rs 41 to Rs 43 per share for a Rs 11.61 crore SME fresh issue. The Goldline Pharmaceutical IPO is generating one of the highest grey market premiums of any SME IPO currently open, with GMP at Rs 16 to Rs 17 as of 11 May 2026, signalling an expected listing gain of approximately 37 to 40 percent over the upper band of Rs 43. The implied listing price based on current GMP stands at approximately Rs 59 to Rs 60.<\/p>

Goldline Pharmaceutical Ltd is a Nagpur-based pharmaceutical marketing company founded in 2005 that operates on an asset-light, third-party contract manufacturing model. With 15 contract manufacturers and 8 distributors, the company markets pharmaceutical products across five branded segments under the Goldline brand in Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan and Bihar.<\/p>

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n